ストックスクリーナーアプリを入手
13.73
0.66%
0.09
アフターアワーズ：
13.73
前日終値:
$13.64
開ける：
$13.79
24時間の取引高:
411.17K
Relative Volume:
0.42
時価総額：
$1.44B
収益：
-
当期純損益:
$-115.88M
株価収益率:
-8.8764
EPS:
-1.5468
ネットキャッシュフロー:
$-104.72M
1週間 パフォーマンス:
-1.01%
1か月 パフォーマンス:
-5.24%
6か月 パフォーマンス:
-47.72%
1年 パフォーマンス:
-36.11%
1日の値動き範囲:
$13.68
$14.08
1週間の範囲:
$13.30
$14.17
52週間の値動き範囲:
$10.60
$38.12
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
EWTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
13.73 | 1.46B | 0 | -115.88M | -104.72M | -1.5468 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-30 | 開始されました | H.C. Wainwright | Buy |
| 2025-04-30 | 開始されました | Guggenheim | Buy |
| 2025-04-02 | ダウングレード | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2025-01-22 | 開始されました | Stifel | Hold |
| 2024-11-22 | 開始されました | Evercore ISI | Outperform |
| 2024-03-07 | 開始されました | Piper Sandler | Overweight |
| 2023-05-01 | 開始されました | Truist | Buy |
| 2022-08-25 | ダウングレード | Goldman | Neutral → Sell |
| 2022-04-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-01-28 | 開始されました | Goldman | Neutral |
すべてを表示
Edgewise Therapeutics Inc (EWTX) 最新ニュース
why edgewise therapeutics inc. stock attracts strong analyst attentionFree Professional Portfolio Management - Newser
What makes Edgewise Therapeutics Inc. stock price move sharplyQuick Profit Idea Stream - Newser
How Edgewise Therapeutics Inc. stock performs during market volatilityShort Squeeze Radar - Newser
Why Edgewise Therapeutics Inc. stock attracts strong analyst attentionFree Access to Community - Newser
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc.EWTX - WV News
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Edgewise Therapeutics Reports Positive Results for Muscular Dystrophy Treatment - MSN
(EWTX) Trading Report - news.stocktradersdaily.com
Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap UpHere's What Happened - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Now Covered by HC Wainwright - Defense World
HC Wainwright Initiates Edgewise Therapeutics With Buy Rating, $42 Price Target - MarketScreener
Edgewise Therapeutics (EWTX) Initiated with Buy Rating by HC Wainwright | EWTX Stock News - GuruFocus
Analysts Offer Insights on Healthcare Companies: BeiGene (ONC), Vertex Pharmaceuticals (VRTX) and Edgewise Therapeutics (EWTX) - The Globe and Mail
Edgewise Therapeutics Shares Drop After FDA Withholds Accelerated Approval for Muscle Disorder Drug - MSN
SG Americas Securities LLC Purchases New Shares in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - Defense World
Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies - WV News
Edgewise Therapeutics stock falls after FDA deems data insufficient for accelerated approval - Investing.com UK
Edgewise Therapeutics (NASDAQ:EWTX) Shares Down 3.8%Here's What Happened - MarketBeat
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Stake Boosted by GAMMA Investing LLC - MarketBeat
Rhumbline Advisers Purchases 6,440 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - Defense World
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives $39.78 Average PT from Analysts - MarketBeat
Enliven to sell $200M in stock after positive drug trial - BizWest
Does Edgewise Therapeutics (EWTX) Have the Potential to Rally 174.68% as Wall Street Analysts Expect? - MSN
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Transcript : Edgewise Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 03 - MarketScreener
Bank of America Corp DE Has $1.31 Million Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Receives "Outperform" Rating from Royal Bank of Canada - MarketBeat
Ameriprise Financial Inc. Purchases Shares of 22,584 Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Royal Bank of Canada Reaffirms Outperform Rating for Edgewise Therapeutics (NASDAQ:EWTX) - Defense World
Bank of America Corp DE Decreases Stock Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - Defense World
Edgewise Therapeutics (EWTX) Receives Reaffirmed 'Outperform' Ra - GuruFocus
RBC Capital maintains outperform rating on Edgewise Therapeutics stock By Investing.com - Investing.com India
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Invests $2.40 Million in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics to Present at the Annual Goldman Sachs Global Healthcare Conference - Eastern Progress
Muscle Disease Leader Edgewise Therapeutics Set for Key Goldman Sachs Healthcare Conference Presentation - Stock Titan
Two Sigma Investments LP Has $3.52 Million Stock Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Certain Stock Options of Edgewise Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 2-JUN-2025. - marketscreener.com
Certain Common Stock of Edgewise Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 2-JUN-2025. - marketscreener.com
(EWTX) Technical Data - news.stocktradersdaily.com
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Shares Purchased by Nuveen Asset Management LLC - MarketBeat
Polar Asset Management Partners Inc. Has $1.72 Million Stock Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics: Upcoming DMD Trial Data May Disappoint (NASDAQ:EWTX) - Seeking Alpha
Edgewise Therapeutics Inc (EWTX) 財務データ
収益
当期純利益
現金流量
EPS
0.64%
0.37%
大文字化:
|
ボリューム (24 時間):